In light of the vital role mining plays within the economy, the government recently detailed plans for Australia to become a leading global supplier of resources services over the next decade.
Read More
Brokers have walked away from Aristocrat’s recent investor briefing incrementally more confident the company will emerge post-covid in a stronger competitive position
Read More
When small-cap promo sites morph into fund managers, it’s time to scrutinise which stocks are being covered, why, and who is bringing them to your attention.
Read More
Confusion between investing and gambling severely compromises your ability to accumulate long-term wealth: Do you know the difference?
Read More
While bonds yields have risen on higher inflationary expectations, driven by higher commodity prices and expectations surrounding large US fiscal stimulus, the big unknown is what will happen next?
Read More
Despite uncertainty following the Royal Commission, a more immediate funding response is expected to find its way to the listed providers, and likely boost FY21 earnings.
Read More
Dwindling appetite for exploration, a pandemic-driven drop in global demand, and US shale operators seemingly running out of puff, have all coalesced to make the ‘perfect storm’ of higher prices and limited supply that is brewing for OPEC.
Read More
Tsingshan’s battery contract triggers nickel over-supply concern. Major steel production cuts mooted. Is an oil price consolidation period due? Bulks well supported, demand cooling for base metals. Gold loses appeal.
Read More
A decision by the EU last year to recalibrate the ecosystem around the manufacturing of electric vehicles (EVs), has serious implications for suppliers of minerals to battery and EV producers globally.
Read More
While Service Stream has indicated its second half would continue to be weak, material wins under NBN Co’s upgrade program could be an important swing factor.
Read More
GeneticSignatures (ASX: GSS) a specialist molecular diagnostics (MDx) company, plans to leverage its existing suite of real-time screening products into an expanding customer base.
Read More
Australian oncology-focused company, Kazia Therapeutics has just announced a license agreement with Swedish speciality pharmaceutical company Oasmia Pharmaceutical for its ovarian cancer drug Cantrixil.
Read More
Taking a ground-floor position in listed hydrogen stocks could return in spades over time. Mark Story explains why.
Read More
